NEW YORK, May 10, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against INSYS Therapeutics, Inc. (“INSYS” or the “Company”) (NASDAQ:INSY) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased INSYS securities between February 23, 2016 and March 15, 2017, both dates inclusive (the "Class Period"). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/insy.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) as a result, INSYS lacked effective internal controls over financial reporting; and (4) consequently, the Company’s public statements were materially false and misleading at all relevant times.
On March 15, 2017, after-market hours, INSYS announced that it postponed filing its financial results for the quarter and year ended December 31, 2016. INSYS told investors that “[t]he Audit Committee of the Company’s Board of Directors has been conducting an independent review of the Company’s processes related to estimation of, and increases to, certain sales allowances recorded during 2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended payment terms offered to certain customers during the third quarter of 2016.” Following this news, INSYS stock dropped $0.49 per share, or 4.64%, to close at $10.06 on March 16, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/insy or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



